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ABSTRACT
Mathematical models are useful for assessing the potential epidemiological impact of future tuberculosis
(TB) vaccines. We conducted a systematic review of mathematical models estimating the epidemiological
impact of future human TB vaccines. PubMed, Embase and WHO Global Health Library were searched, 3-
stage manual sifted, and citation- and reference-tracked, identifying 23 papers. An adapted quality
assessment tool was developed, with a resulting median study quality score of 20/28. The literature
remains divided as to whether vaccines effective pre- or post-infection would provide greatest
epidemiological impact. However, all-age or adolescent/adult targeted prevention of disease vaccines
achieve greater and more rapid impact than neonatal vaccines. Mass campaigns alongside routine
neonatal vaccination can have profound additional impact. Economic evaluations found TB vaccines
overwhelmingly cost-effective, particularly when targeted to adolescents/adults. The variability of impact
by setting, age group and vaccine characteristics must be accounted for in the development and delivery
of future TB vaccines.
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Introduction
Although Bacillus Calmette–Guerin (BCG) is a longstanding
cornerstone of the Expanded Programme on Immunization
(EPI) schedule, the only licensed vaccine against tuberculosis
(TB) disease, and one of the most widely used vaccines world-
wide, it provides variable protection against pulmonary forms
of tuberculosis disease and an uncertain duration of protec-
tion.1,2 Tuberculosis is responsible for the largest number of
annual deaths from a single infectious agent, estimated at
1.5 million in 2014, of which 91% were adults.3 Of 9.6 million
incident cases, 37% were undiagnosed or unreported.3 Hence
there remains a substantial unmet need for preventative meas-
ures such as new TB vaccines, particularly for protection
against pulmonary disease in adult populations, which is clini-
cally challenging to manage as well as being the source of most
on-going transmission. It is a widely held view that new TB
vaccines will be essential to the efforts to meet the World
Health Organization (WHO) End TB Strategy 2035 goals and
WHO 2050 goal of elimination of TB as a public health prob-
lem.3-5 With 15 candidates currently in clinical trials, including
one in each of phase IIb and III, the current TB vaccine pipeline
is the most promising to date.3
The ﬁeld is yet to see clinical efﬁcacy in a novel candidate
and the lack of an immunological correlate of protection for
TB makes identifying promising candidates challenging,
therefore clinical trials are long and costly, with limited guaran-
tee of success. Mathematical models are invaluable tools for
exploring the potential epidemiological impact of different
future vaccine proﬁles and implementation strategies. They can
inform the development of target product proﬁles and clinical
development plans leading to vaccine candidates ready for
licensure in the target populations in which they would have
the greatest population-level impact. Modeling results are also
important in advocating for vaccine development and
investment.
The TB vaccine pipeline consists of a variety of vaccine pro-
ﬁles. Novel TB vaccine proﬁles can be categorized into four
dimensions: the host infection status required for efﬁcacy (pre-,
post- or, pre- and post-infection: PRI, PSI and P&PI), an effect
type (prevention of infection, disease, or infection and disease:
POI, POD or POI&D), an efﬁcacy, and a duration of protection
(see Table 1 for deﬁnitions and abbreviations). Maximization
of vaccine efﬁcacy and duration of protection is obviously
desirable, but given the challenges faced in TB vaccine develop-
ment, a partially protective vaccine with limited duration of
protection is a likely outcome. Similarly, a P&PI and a POI&D
vaccine would have greatest impact, but given this may not be
possible, less is known about the relative advantages of efﬁcacy
with different host infection status and effect types, particularly
when considering extrinsic factors such as the age-structure
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and temporal trends of local epidemiology and other control
measures. Therefore, modeling is a logical framework for esti-
mating the inﬂuence of such factors on the population-level
impact of future vaccines. This is important for rational
development of target product proﬁles, minimum acceptable
proﬁles, identifying target populations for vaccination, and esti-
mating cost effectiveness of such vaccines.
As a growing ﬁeld of research, publication of mathematical
models assessing the potential impact of future TB vaccines has
increased in recent years, yet no systematic review exists of this
literature. Given the importance of this information for rational
decision making in TB vaccine development and the strength of
the current pipeline, a review of the literature was considered of
importance. We therefore conducted a systematic review of pub-
lished literature to answer the research question: what is the epi-
demiological impact of future human TB vaccines delivered to
any age group when compared to no vaccination, other future
vaccine proﬁles or other TB control interventions, as estimated
using mathematical models? The aim was to provide a summary
of the modeling methodology used, the characteristics of future
TB vaccines explored using modeling, and the comparative epi-
demiological impact of such novel vaccine proﬁles.
Methods
PICOS framework
The PICOS framework was employed to deﬁne the review
research question (Table S1). Searches were restricted to human
studies. The interventions of interest were future, new, pipeline
or theoretical vaccines for human tuberculosis. Papers exploring
the impact of a single, deﬁned-efﬁcacy BCG vaccine were
excluded; however, those exploring impact of a nominally BCG
vaccine but with varying vaccine efﬁcacy were considered for
inclusion as these could be considered reﬂective of other theoreti-
cal vaccines. A broad deﬁnition was applied for the comparator of
interest, therefore studies comparing new vaccines to no vaccine,
BCG-only, alternative new vaccines or alternative currently avail-
able interventions were considered. Only articles reporting epide-
miological outcomes, such as the impact on rates or absolute
numbers of incidence, prevalence or mortality, or alternatively
the number needed to vaccinate per case/death averted or cost-
effectiveness measures, were included. Within-host impact mod-
els exploring immunological outcomes were excluded. The
research question focused on the use of mathematical modeling
as the study design. Narrative reviews and commentaries were
excluded unless providing new modeling analyses or outcomes.
No limits were placed upon publication dates.
Search strategy
Three electronic healthcare sources (PubMed, Embase and
WHO Global Health Library) providing access to seven data-
bases (PubMed/Medline, Embase, African Index Medicus,
LILACS, SEARO Index Medicus, WPRO Index Medicus,
EMRO Index Medicus) were searched. A comprehensive search
strategy was developed using the deﬁned PICOS framework,
using free text and Mesh/Emtree/DeCS terms tailored by data-
base for groups of terms covering tuberculosis, vaccines and
modeling (Table S2). All searches were run with the “human”
ﬁlter, and the WHO Global Health Library search was limited
to regional databases to avoid duplication. No language or pub-
lication type limits were applied. Searches were conducted on
the 12th January 2016.
Study selection and data extraction
This research was conducted in accordance with the York Cen-
tre for Reviews and Dissemination guidance for undertaking
reviews in healthcare.6 Three-stage manual sifting of titles,
abstracts, then full texts was employed by the primary reviewer
to apply the pre-deﬁned inclusion/exclusion criteria described
in Table 2. Where uncertainty with regards to inclusion at full
text existed, a low threshold was used to trigger assessment by a
second reviewer (TS). Reasons for exclusion at the full text
stage were recorded. Data were extracted from eligible papers
into a piloted, standardized Excel database by a ﬁrst reviewer
(RH), and fully checked by a second (TS/RW). Reference lists
were hand searched and onward citation searching was con-
ducted using Web of Science for all included studies.
Table 1. Vaccine proﬁle deﬁnitions.
Vaccine characteristic Terminology Deﬁnition Abbreviation
Host infection status
required for efﬁcacy a
Pre-infection Protects when delivered to uninfected populations. Does not protect
when delivered to infected or previously infected populations.
PRI
Post-infection Protects when delivered to latent (and/or recovered) populations. Does
not protect when delivered to uninfected populations.
PSI
Pre- and post-infection Protects when delivered to uninfected, latently infected or recovered
populations
P&PI
Effect type (infection/disease
transition protected against)
Prevention of infection Effective against the acquisition of M.tb infection (uninfected to infected
state)
POI
Prevention of disease Prevents progression to active disease (uninfected or infected to disease
state)
POD
Prevention of infection and disease Prevents both infection and development of disease POI&D
Efﬁcacy Vaccine efﬁcacy Protection provided by the vaccine. Can be “take” or “degree” VE
Duration of protection Duration of protection Time during which vaccine remains efﬁcacious. May include waning of
protection
—
aM.tb exposure without infection, and immune priming with BCG or another vaccine, are not included within this deﬁnition, as exposure would not impact vaccine
response, and priming could be under the control of the public health system.
2 R. C. HARRIS ET AL.
Qualitative synthesis of extracted data was employed to pro-
duce a narrative summary of included literature.
In accordance with PRISMA methodology, a protocol sum-
mary is registered on PROSPERO (reference: CRD42016033266)
and the full protocol and PRISMA checklist are available in sup-
plementarymaterials (Supplementary appendix C and Table S4).7
Assessment of quality
We developed a new adapted tool for assessment of modeling study
quality and risk of bias (Table S3). This built upon previously pub-
lished frameworks for health relatedmodeling and health economic
modeling.8,9 By adding four more criteria to the Fone tool we
allowed a more in-depth consideration of deﬁnition of model set-
ting and population, appropriateness of modeling methodology
and structure, ﬁtting methodology, and reporting of conﬂicts of
interest, which are essential for assessing the reproducibility of the
model, alignment of the model and research question, and risks of
bias.8 To improve usability, the adapted tool presented contains the
questions to be considered for each of the 14 criteria and clear guid-
ance on the rating of zero, one or two for each criterion. If a criterion
was not relevant for a particular paper, a score of one was assigned
so as not to unduly bias the scores in either direction. Papers were
scored 0-2 on each of 14 criteria, giving a maximum score of 28
points. A quality of “low” (<14), “medium”(14-18), “high” (19-22)
or “very high” (>22) was assigned based upon the overall score.
Assessment of quality was conducted by one reviewer
(RCH), but with a low threshold for examining any uncertain
scores by a second reviewer (TS). The second reviewer also
Table 2. Inclusion and exclusion criteria applied in manual screening of articles.
Inclusion Criteria
Mathematical model
Systematic review of models of novel/future/hypothetical TB vaccine, or
commentary adding to the analyses/interpretation of models reported
elsewhere
Intervention is novel/future/hypothetical vaccine against tuberculosis
or of an unspeciﬁed novel TB intervention with characteristics in-line
with a vaccine
Reported outcomes are of the epidemiological impact of vaccine(s)
(e.g. incidence, prevalence, mortality, number needed to vaccinate,
cost effectiveness)
Exclusion Criteria
Within-host/immunological vaccine impact models
Review or commentary not adding to existing body of knowledge
TB epidemiological models not reporting impact of vaccine
TB epidemiological models reporting only interventions other than
vaccines
Model only reporting on impact of BCG with single known/ﬁxed efﬁcacy
Disease or infection caused by Mycobacterium bovis or other
non-Mycobacterium tuberculosis strain.
Pubmed: n = 843 Embase: n = 64 WHO GHL: n = 12
Total hits, n = 919
Records screened at abstract 
level, n = 128
Records screened at full text 
level, n = 37
Studies included, n = 17 
Studies removed  
756
Studies removed at abstract 
level: 91
Studies removed at full text level, n=20:
Single profile BCG only: 3
Full text not available: 2
2
Commentary: 6
No epidemiological outcomes: 5
Other: 2
Final studies included, n = 23 
Studies included from (n=6):
References: 3
3
Duplicates removed, abstracts 
screened level, n = 884
Figure 1. Summary of systematic screening of identiﬁed articles.
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reviewed one paper from each quality level to check for agree-
ment with the scoring and overall assessment of quality. Due to
potential conﬂicts of interest, one paper was also reviewed by a
third reviewer (SR).
Results
Screening process
A total of 919 records, comprising 884 unique articles after
removal of duplicates, were identiﬁed (Fig. 1). Title screening
removed 756 articles, and abstract screening a further 91, yield-
ing 37 articles for review at full text. Twenty articles were
excluded from the review during full text screening. The two
most common reasons for exclusion were commentaries pro-
viding no additional analysis (n D 6) and articles without epi-
demiological outcomes (n D 5). Reference and citation sear-
ching identiﬁed 6 additional articles for inclusion, therefore 23
research articles were included in the review (Table 3).
Although one BCG-based TB vaccine model exists from the
1960s,10 two models published in 1998 were the ﬁrst to explore
entirely novel TB vaccine proﬁles,11,12 and the majority (20/23)
of included papers have been published since 2000,4,13-31 moti-
vated by the promising late-stage pipeline and the push to
attain challenging WHO/Stop TB global TB targets.
Modeling methods (n D 23)
The included studies comprised 18 deterministic, compartmen-
tal, dynamic models constructed using difference or differential
equations,4,10-14,16-21,23-25,27-29 3 Markov decision tree analy-
ses,15,22,31 one a simple mathematical model including a ﬁxed
number of transmissions per case,30 and one statistical model.26
A subset of these papers (n D 5) present analytical solutions of
models and discuss the theoretical implications of a range of
factors on the impact of vaccines.11,13,17,25,26 These 5 papers do
not provide any quantitative estimates of the epidemiological
impact of novel vaccines and are not discussed further. A sum-
mary of model structures and ﬁtting methods is provided in
supplementary appendix A.
Vaccine characteristics (n D 18)
Modeled vaccine characteristics are summarized in Table 3. An
anticipated vaccine efﬁcacy in the range of 40–80% was most com-
monly modeled,10,12,15,18,20-22,27-31 though some explored the public
health impact of the extremes above15,20,29 or below 10,12,22,29 this
range. Vaccine efﬁcacy was modeled as ‘take’ (i.e. a proportion of
those vaccinated are completely protected, also known as an “all-
or-nothing” vaccine) in 6 studies,4,16,22,24,27,30 and as ‘degree’ (i.e.,
all vaccinees receive some protection from the vaccine, sometimes
known as a ‘leaky’ vaccine) in 8 studies.10,12,14,15,18,20,21,31 One study
modeled efﬁcacy as a combination of take and degree.28 The type
of vaccine efﬁcacy was not possible to identify in three stud-
ies.19,23,29 Those studies explicitly modeling vaccine coverage
tended to model coverage of 80–100%,10,12,15,20-22,27-31 though
some included lower coverages.12,20,27 Only one study assumed
coverage using data reﬂective of country- and age-speciﬁc access to
the healthcare system.27 Some studies use a combined parameter
(‘proportion effectively immunized’) of vaccine efﬁcacy multiplied
by coverage.4,16,19,23,24Where the proportion effectively immunized
was not reported, we estimated the approximate proportion at
ﬁve years after vaccine implementation. The scenarios of the pro-
portion effectively immunized spanned a wide range in most stud-
ies, ranging from a lower limit of 9–38% to upper limit of 70–
95%,10,20,22,24,27,29,30,32 though some studies did employ lower upper
limits,4,12,15,16 and some explored just a single scenario of propor-
tion effectively immunized within the range 44-70%.19,21,23,28,31 In
two studies it was not possible to estimate the proportion effectively
immunized.14,18
Most often, duration of vaccine protection was assumed to
be 10 years15,20,22,24,27,30,31 or lifelong,4,16,27,28 with some assum-
ing alternative scenarios including 5, 30 and 33 years protec-
tion.20,21,27,31 Seven articles did not report the duration of
protection modeled,10,12,16,18,19,23,29 but several appeared to use
lifelong protection.10,16,29 Waning of protection has been mod-
eled as either exact (all depart the vaccinated state exactly at the
end of duration),4,14,16,24,27,28,31 or linear or exponential waning
throughout the duration of protection.15,21,31
Many of the modeling studies explored the impact of multi-
ple vaccine proﬁles assuming various effect types and/or host
infection statuses required for efﬁcacy. The post-infection (PSI)
vaccines modeled assumed a prevention of disease (POD) vac-
cine effect,4,12,14,19-21,28 or prevention of infection and disease
(POI&D) effect.4,16 Pre-infection (PRI) vaccines have been mod-
eled assuming a prevention of infection (POI),4,12,16,18,23,24,29
POD,4,10,15,19,21,22,30,31 or POI&D vaccine effect.14,20,28 Com-
bined pre- and post-infection (P&PI) vaccines have been mod-
eled assuming a POI&D16 or POD12,19,21,23,27 vaccine effect. The
most frequently explored effect types were pre-infection vac-
cines with prevention of disease 4,10,15,19,21,22,30,31 or prevention
of infection 4,12,16,18,23,24,29 effect, and post-infection vaccines
with prevention of disease effect.4,12,14,19-21,28
Targeting of vaccination to populations with a speciﬁc host
infection status (n D 12) was common in the models identi-
ﬁed,4,10,12,16,18-21,24,28,29,31 as was targeting to speciﬁc age groups
(n D 12).10,12,15,18,19,21,22,24,27,28,30,31 Pre-infection vaccines were
most frequently targeted to neonates as they were a mostly
uninfected population,10,15,18,19,21-23,28,30,31 occasionally with an
adolescent boost21,31 or with a one-off mass campaign to all
ages.10,19,23,28 However, several studies included an analysis of
the impact of pre-infection vaccines in adolescent,24 high
risk,18 or all-ages mass vaccination campaigns or routine
immunization.12,20,21,28,29 Post-infection vaccines have mostly
been modeled as delivered to all ages,4,19-21,28 and in several
studies age targeting is not stated but is thought to be delivered
to all ages.4,14,16 Pre- and post-infection vaccines have been
modeled as delivered to neonates,23,27 neonates with short term
all-age mass campaigns,12,23 routine adolescent vaccination
with adult mass campaigns,27 or delivered to all ages.19,21
Setting and population (n D 18)
Three were global studies,12,14,16 two regional studies (e.g.
WHO regions),19,21 one in low- and middle-income coun-
tries,27 four based upon hypothetical high burden set-
tings,4,10,20,28 three were set in South Africa,15,22,24 one in
Japan,30 one in Zambia,31 one in a hypothetical township,29 one
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in a developed country,18 and one where the setting was not
clearly stated.23 Two of the afore-mentioned studies also
reported on country- (China, India and South Africa) or
region-level models in addition to the main model reported.4,12
Only two of the 18 studies consider heterogeneous social
mixing patterns: one included mixing by HIV status,12 and one
household model considers different mixing patterns during
community, diurnal interactions and familial interactions at
night.29
A small number of studies included risk groups within the
modeled population. HIV status is largely neglected in TB vac-
cine modeling, a surprising fact given its importance as a driver
of the TB epidemic in Africa and parts of Asia, but perhaps
linked to this population being largely excluded from vaccine
trials. One model targeted vaccination exclusively to the HIV-
negative population.24 Only four models explicitly include HIV
stratiﬁcation.12,15,27,31 Two of the Markov decision tree models
included the impact of HIV on TB natural history parameters,
and assumed that the vaccine was equally efﬁcacious in early-
stage HIV infection and HIV uninfected individuals, but had
zero efﬁcacy in patients with AIDS.15,31 Two globally-focused
dynamic models included HIV strata, one of which did not
alter vaccine efﬁcacy in the HIV stratum,12 and the other
accounted for immunocompromise through reduced vaccine
efﬁcacy in HIV-infected patients.27 Two of the models with
HIV strata did not explicitly include antiretroviral therapy
(ART) in the model.12,31 The Ditkowsky study assumed 58%
ART coverage which provided a 75% and 9.8% decrease in
HIV-related annual mortality for those with early HIV and
clinical AIDS, respectively, and a 61% reduction in the risk of
progression to clinical AIDS (with associated higher risks of TB
disease).15 In the Knight model, receipt of ART doubled life
expectancy, decreased rates of progression to TB disease or
death, and halved the reduction in vaccine efﬁcacy experienced
due to HIV infection.27 Aggressive ART scale up was assumed
between 2012 and 2020, increasing from the 2009 coverage
value in each country by half the difference between the 2009
value and 100%.27
Epidemiological impact of future TB vaccines (n D 18)
Fourteen studies had the epidemiological impact4,12,16,18-
21,23,28,29 and/or cost effectiveness 15,22,27,31 of future TB vaccine
candidates as a primary focus. Three studies explored the
impact of a variable efﬁcacy BCG vaccination.10,24,30 One strain
competition model explored impact of differential vaccine
effectiveness by strain.14 Details of the vaccine proﬁles and out-
comes discussed are summarized in Table 3.
i. Age targeting: Neonatal versus all ages, adolescents
or adults
Only one study offered a clear comparison of targeting a given
vaccine to neonates compared to adolescents/adults.27 Two
studies model the impact of vaccines delivered to neonates
compared to delivery to all ages.21,28
In the study by Knight et al., implementation of routine ado-
lescent vaccination with periodic mass adult campaigns was
found to have a much greater impact than routine neonatal
vaccination with a prevention of disease vaccine in low- and
middle-income countries across the 2024-50 time horizon.27
For example, a 60% efﬁcacious vaccine providing 10 years pro-
tection could prevent 17 million (range 11–24m) cases between
2024-2050 when delivered to adolescent/adults compared to
just 0.89 million (range 0.42–1.58m) when delivered to neo-
nates.27 The vaccine coverage differed in each age targeting sce-
nario, based upon data from current vaccination campaigns
relevant to those populations and so might be considered a
more realistic reﬂection of achievable coverage. There are likely
greater cost and logistical implications of delivering an adoles-
cent/adult vaccine than a routine neonatal vaccine, however in
this study it was found that due to the greater impact achieved
when vaccinating older age groups, all of the vaccine proﬁles
explored in this age group had a cost effective price per vaccine
dose, whereas for neonatal vaccination some of the shorter
durations of protection and lower vaccine efﬁcacies were not
considered cost effective. It was noted in the article that some
conclusions may be timeframe dependent, as those receiving
neonatal vaccination with long durations of protection would
only just be reaching the age of high TB risk in 2050.
As would be expected, vaccinating all ages had a greater
impact (80% incidence rate reduction over a 35-year time hori-
zon) compared to vaccinating neonates with an adolescent
boost (39% incidence rate reduction) with a POD vaccine in
the Abu-Raddad study.21 Though it should be noted that the
number vaccinated would be much greater in the all-ages sce-
nario. In the other neonatal vs. all-ages study,28 routine neona-
tal vaccination was compared to a one-off mass campaign for
uninfected individuals of all ages with a POI&D vaccine. In this
study, mass vaccination of all ages initially provides greater epi-
demiological impact than neonatal vaccination. As the vacci-
nated cohort ages out the incidence rates rebound, whereas
with sustained routine neonatal vaccination incidence rates
continue to decline, and provide greater impact than a one-off
mass campaign after approximately 20 years.28
No studies were found comparing vaccinating neonates to
all ages or adults with prevention of infection vaccines, or of
combining such age targeting with targeting of post-infection
populations.
ii. Addition of mass campaigns or boosters to routine
neonatal vaccination
Three studies found that the addition of one-off mass vaccina-
tion campaigns on top of neonatal routine vaccination could
have profound effects on population-level impact.19,23,28 In a
South-East Asian study exploring impact of a pre-infection pre-
vention of disease vaccine over a 35 year time horizon, an inci-
dence rate reduction of approximately 65% was predicted with
a neonatal vaccine, compared to >90% when adding a one-off
mass campaign at launch.19 In another study, addition of a
one-off mass vaccination campaign to the routine neonatal pro-
gram (with 70% of the population protected in each group)
increased the reduction in incidence rate from around a quarter
to approximately 85% over 25 years.23 In the Lietman study,
addition of a one-off mass campaign to routine neonatal vacci-
nation greatly increased the short-term impact of the
program.28
One study assessed the impact of an adolescent booster in
addition to neonatal vaccination, which in a Markov model
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was found to double the number of cases averted compared to
neonatal vaccination alone.31
iii. Host infection status required for efﬁcacy: Pre-infection,
post-infection or pre- and post-infection
Eight studies report a comparison of vaccines effective in differ-
ent host infection statuses,4,12,14,16,19-21,28 of which six report
clear comparisons between vaccines effective pre- versus post-
infection.4,16,19-21,28
Exploring the impact on disease incidence, three studies sug-
gest post-infection vaccines would have the greatest
impact,4,20,28 two suggest pre-infection would provide greatest
impact,19,21 and one suggests that either could have greater
impact, dependent upon the rate of treatment of active dis-
ease.16 The six studies allowing comparison are described
below.
iii.a. Post-infection vaccines leading to greater impact on
disease incidence (n D 3). The Ziv, Lietman and Dye (2013)
models report post-infection vaccines as providing greater
impact on disease incidence than pre-infection vaccines.4,20,28
Ziv et al., compared the effect of POD vaccines targeted to
uninfected (pre-infection) or infected (post-infection) popula-
tions in a hypothetical high burden setting with 28-50% latently
infected and 40-60% of active cases treated and cured, and
reported that post-infection vaccines would have a greater and
more rapid effect on cumulative number of incident cases than
pre-infection vaccines.20 After 10 years, post-infection vaccines
prevented 34% of cumulative cases compared to 23% by pre-
infection vaccines.20 Given 28-50% of the population were
latently infected, the number vaccinated with the post-infection
vaccine will be lower in most scenarios, therefore greater
impact on overall disease incidence is achieved despite being
given to fewer individuals. Age targeting, vaccine efﬁcacy and
coverage of target population were identical between scenarios
and both were assumed to prevent development of disease,
though in the pre-infection scenario the vaccine was addition-
ally assumed to have POI activity, and therefore was a POI&D
vaccine.
Similarly, in the Lietman study the pre-infection vaccine was
POI&D whereas the post-infection vaccine was POD-only, but
again, when comparing otherwise identical vaccines, post-
infection vaccination provided the largest and fastest impact on
the disease incidence rate.28 In a background of 50% successful
cure of active disease, comparing 88% coverage of latents
with a post-infection vaccine, to vaccinating 88% of newborns
with a pre-infection vaccine, impact was observed more rapidly
with the post-infection vaccine, and 60 years later the disease
rates with a post-infection vaccine were still lower.28 The sizes
of the latent and newborn populations are not reported, but
they are unlikely to be equal, therefore the number of people
effectively vaccinated and therefore the number needed to vac-
cinate per case averted in each of these scenarios could be very
different. Even if routine neonatal pre-infection vaccination
was preceded by a one-off mass campaign, the initial impact
was still not as large as the post-infection vaccine, but in this
scenario after 40 years the overall incidence rate reduction was
similar.
In a study by Dye et al., in a “typical high burden country”
with 110 cases per 100,000 population per year and 65% case
detection, of which 70% are cured, effective immunization of
25%/year of the uninfected population (pre-infection) with a
POI vaccine reduced disease incidence rates to 130/million
population/year, whereas as little as 14%/year effective immu-
nization of latents (post-infection) with a POD vaccine reduced
the incidence much further to 20/million population/year.4
In all three studies reporting greater impact of post infection
vaccines, the proportion assumed effectively immunized was
lower in the post-infection vaccine target group.4,20,28 There-
fore, even with lower coverage, post-infection achieved greater
impact than pre-infection vaccines.
iii.b. Pre-infection vaccines leading to greater impact on
disease incidence (n D 2). In the Abu-Raddad and Young
models,19,21 pre-infection vaccines demonstrated greater
impact on disease incidence than post-infection vaccines. In
the Abu-Raddad model, campaigns targeted at latently infected
individuals (post-infection) compared to mass vaccination
campaigns using pre-infection or P&PI vaccines, predicted
incidence rate reductions of 37%, 80% and 92% over a 35 year
time horizon, respectively.21 The Young study was also a South
Asian model, which compared the impact of otherwise-identi-
cal PRI, PSI and P&PI vaccines implemented in 2015.19 The
model estimated an incidence rate of approximately 20, 50, and
14 per 100,000 population per year in 2050, indicating that the
most effective vaccine in this scenario would also be a pre-
infection or P&PI vaccine.19 Though it should be noted that
there was some ambiguity in the article as to the vaccine sched-
ule, therefore there may be confounding due to differences in
schedules modeled. Both the Abu-Raddad and Young models
assumed that the pre-infection vaccines were prevention of dis-
ease vaccines, so would not have had a direct effect on
infection.
iii.c. Research indicating a possible reason for such contrasting
results (n D 1). A ‘global’ study excluding sub-Saharan Africa
found that at low active disease treatment rates pre-infection
vaccines providing lifetime protection had greater impact on
disease incidence rates than equivalent targeting of post-infec-
tion vaccines.16 However, when treatment rates of active disease
were increased, reducing the proportion of disease from recent
infection compared to reactivation, the post-infection vaccine
was reported to have greater impact on disease incidence. We
discuss this more below.
iii.d. Other factors inﬂuencing comparison of impact of pre- or
post- infection vaccines. Although the proportions effectively
immunized (coverage multiplied by vaccine efﬁcacy) did not
differ markedly between studies favoring pre- or post-infection
vaccines, the proportion of the population latently infected will
co-determine the number of people that would receive either a
pre- or post-infection vaccine, and could be an important cause
of differences. However, only two of these six studies reported
the assumed infection prevalence.16,20
Time horizon could be important for this comparison. As
demonstrated in the Ziv and Lietman models,20,28 even though
post-infection vaccines may have greater initial impact, the
HUMAN VACCINES & IMMUNOTHERAPEUTICS 13
Ta
bl
e
4.
Q
ua
lit
y
as
se
ss
m
en
to
fi
nc
lu
de
d
m
od
el
in
g
st
ud
ie
s.
Au
th
or
Ye
ar
Ai
m
s
an
d
ob
je
ct
iv
es
Se
tt
in
g
an
d
po
pu
la
tio
n
In
te
rv
en
tio
n/
co
m
pa
ra
to
rs
O
ut
co
m
e
m
ea
su
re
s
M
od
el
st
ru
ct
ur
e
an
d
tim
e
ho
riz
on
M
od
el
in
g
m
et
ho
ds
Pa
ra
m
et
er
s,
ra
ng
es
an
d
da
ta
so
ur
ce
s
As
su
m
pt
io
ns
ex
pl
ic
it
an
d
ju
st
iﬁ
ed
Q
ua
lit
y
of
da
ta
an
d
un
ce
rt
ai
nt
y
an
d/
or
se
ns
iti
vi
ty
an
al
ys
es
M
et
ho
d
of
ﬁ
tt
in
g
M
od
el
va
lid
at
io
n
Pr
es
en
ta
tio
n
of
re
su
lts
an
d
un
ce
rt
ai
nt
y
In
te
rp
re
ta
tio
n
an
d
di
sc
us
si
on
of
re
su
lts
Fu
nd
in
g
so
ur
ce
an
d
co
nﬂ
ic
ts
of
in
te
re
st
Fi
na
lS
co
re
(/
28
)
Ra
tin
g
Ab
u-
Ra
dd
ad
20
09
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
N
o
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
23
Ve
ry
hi
gh
Bh
un
u
20
08
Ye
s
N
o
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
N
o
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
16
M
ed
iu
m
Ca
st
ill
o-
Ch
av
ez
19
98
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
20
H
ig
h

Ch
an
ni
ng
20
14
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
N
o
Ye
s
Pa
rt
ia
l
Ye
s
24
Ve
ry
hi
gh
Co
he
n
20
08
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Ye
s
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
19
H
ig
h
D
itk
ow
sk
y
20
14
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
N
o
Ye
s
Ye
s
Ye
s
25
Ve
ry
hi
gh
D
ye
20
00
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
N
o
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Pa
rt
ia
l
N
o
11
Lo
w
D
ye
20
08
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
N
o
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
20
H
ig
h
D
ye
20
13
a
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
Ye
s
N
o
Ye
s
Ye
s
Pa
rt
ia
l
23
Ve
ry
hi
gh
D
ye
20
13
b
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
N
o
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
18
M
ed
iu
m
G
om
es
20
04
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
17
M
ed
iu
m

G
om
es
20
07
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
17
M
ed
iu
m

H
aw
n
20
14
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
N
o
Ye
s
Pa
rt
ia
l
Ye
s
18
M
ed
iu
m

Kn
ig
ht
20
14
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
Ye
s
N
o
Ye
s
Ye
s
Ye
s
25
Ve
ry
hi
gh
Li
et
m
an
20
00
Ye
s
N
o
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
N
o
Pa
rt
ia
l
N
o
N
o
N
o
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
14
M
ed
iu
m
M
ur
ra
y
19
98
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
N
o
Ye
s
Ye
s
N
o
23
Ve
ry
H
ig
h
Pi
en
aa
r
20
10
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
N
o
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
18
M
ed
iu
m
Ra
hm
an
20
01
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
N
o
Ye
s
Ye
s
N
o
21
H
ig
h
Re
ve
lle
19
67
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
N
o
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
20
H
ig
h
Ro
dr
ig
ue
s
20
09
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
N
o
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
18
M
ed
iu
m

Ts
en
g
20
11
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
N
o
Ye
s
Ye
s
Ye
s
24
Ve
ry
hi
gh
Yo
un
g
20
06
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
Pa
rt
ia
l
N
o
N
o
N
o
Pa
rt
ia
l
Pa
rt
ia
l
N
o
12
Lo
w
Zi
v
20
04
Ye
s
Pa
rt
ia
l
Ye
s
Ye
s
Ye
s
Pa
rt
ia
l
Pa
rt
ia
l
Ye
s
Ye
s
N
o
N
o
Ye
s
Pa
rt
ia
l
Ye
s
20
H
ig
h
M
ed
ia
n
sc
or
e
2
1
1
2
1
2
1
2
1
1
0
1
2
1
20
H
ig
h
 A
na
ly
tic
al
m
od
el
in
g
pa
pe
rs
.
14 R. C. HARRIS ET AL.
impact of the vaccine types sometimes converge over longer
time horizons due to the greater time lag before impact is
observed with pre-infection vaccines. However, all six studies
explore outcomes over a narrow horizon of 35-43 years and
therefore between-study differences in the impact of pre- vs.
post-infection vaccines do not appear attributable to time hori-
zon.4,16,19-21,28 Durations of protection, and effect type for post-
infection or pre-infection vaccines all vary between models, but
were also somewhat similar in both groups.
iv. Disease stage protected against: POI, POD or POI&D
Dye et al. (2000) compared POI and POD vaccines with 70%
effective immunization in a mass campaign followed by neona-
tal vaccination. In this study, the incidence rate reduction was
greater with the POD vaccine than the POI vaccine over a 25
year time horizon.23 In the Murray et al. global model, sus-
tained mass vaccination with 66% coverage of uninfected indi-
viduals for a POI vaccine prevented fewer cases (10.5m-37.0m
cases averted with 20-80% vaccine efﬁcacy over a 17 year time
horizon) than a POD vaccine with mass campaigns scaling up
to 80% coverage over 10 years followed by annual neonatal vac-
cination (16.2m-51.6m cases averted); a trend also reﬂected in
the regional estimates presented.12 However, it must be noted
that there are difﬁculties in identifying whether these are equiv-
alent comparisons given the differences in schedule, size and
infection status of population receiving vaccine and coverage.
Several models explored POI or POD vaccines compared to
a POI&D vaccine. As would be expected since it is a combina-
tion of mechanisms, a number of the studies found the POI&D
vaccine to be most effective.4,14 Those ﬁnding more impact on
disease with the POD vaccine than the POI&D vaccine were
likely confounded by favorable targeting of the vaccines to
latently infected individuals in the POD scenario.20,28
v. Time horizon of impact
The WHO/Stop TB global targets aim to reduce TB incidence
rates to 10 cases per 100,000 population per year by 2035, and
less than 1 case per million population per year by 2050, termed
as tuberculosis elimination.3,5 Several of the studies explored
the potential contribution of future TB vaccines to achieving
the Stop TB 2050 target, but all were published prior to release
of the WHO End TB strategy containing the 2035 goals, so
none directly address these targets. In two papers by Dye et al.,
it was shown that pre-infection POI vaccines to interrupt trans-
mission were unlikely to reach elimination, as even with com-
plete transmission interruption in 2015 an incidence of >100/
million/year would still be expected by 2050.4,16 In the Dye
model, a post-infection vaccine giving full and permanent pro-
tection to 14% of the latently infected population per year was
estimated to reduce incidence to 20/million/year by 2050, and
if combined with treatment of active disease, or a pre-infection
vaccine, would achieve elimination by 2050.4 In country-spe-
ciﬁc models, results suggested that a post-infection vaccine (or
mass preventative therapy) could achieve elimination targets in
China and India.4 These models suggest that a post-infection
vaccine, or either vaccine effect type combined with treatment
of active cases, may be capable of reaching the WHO 2050
elimination goals.4 However, similar models for South Africa
and the USA suggested that elimination was not considered
feasible in these settings with novel vaccines.4 Results from
both the Young and Knight models indicated that none of the
scenarios explored would achieve incidence rates lower than
around 10-20/100,000/year by 2050.19,27
vi. Settings
There was clear variability in vaccine epidemiological impact by
setting. Knight et al. demonstrated a larger proportion and
absolute number of cases would be averted by vaccines in low-
income countries than middle-income countries.27 In Japan,
95% coverage of a BCG-like vaccine with 40-80% vaccine efﬁ-
cacy was considered not cost effective as it could only avert 10-
47 cases per 100,000 children vaccinated over a 10-year hori-
zon.30 Whereas with 92% coverage of a 70% POD vaccine in
the Zambian setting, cases averted were much higher at 199
cases per 100,000 vaccinated at birth;31 though it should be
noted that the Zambian model analyzed a longer 30-year time
horizon. Three models explored the cost effectiveness of adding
booster vaccines in South Africa, but outcomes are not compa-
rable with the Japanese and Zambian models.15,22,24 In two
regional models, for each of the vaccine proﬁles explored the
greatest numbers of cases and deaths avoided were in Asia/
Western Paciﬁc, followed by sub-Saharan Africa (see
Table 3).12,21 Much lower absolute numbers of cases were
avoidable in the other regions, with the next largest impact
observed in the Eastern Mediterranean region where cases
averted were around a third of those in sub-Saharan Africa.21
vii. Economic models
A small number of published studies evaluated the economics
of future TB vaccines (n D 7/18),10,15,22,24,27,30,31 with the
majority (n D 6/7) evaluating cost effectiveness of new vaccines
(either future or BCG based) using either static,15,22,30,31 or
dynamic models.24,27 Optimization techniques were also used
to consider costs associated with different control schemes.10
With the exception of one model exploring a very low efﬁcacy
vaccine and one exploring infant vaccination in a low burden
setting,22,30 those evaluating cost effectiveness found new TB
vaccines to be an overwhelmingly cost effective intervention,
whether from the health system24,27 or societal perspec-
tive.15,27,31 More than half of the models included societal costs,
highlighting that much of the economic burden of TB disease
falls on the TB patient due to the long durations of treatment.
The populations considered in these economic models were
either theoretical10 or setting speciﬁc (South Africa,15,22,24 Zam-
bia31 or Japan30) with only one model considering multiple set-
tings (low- and middle-income countries).27 Cost effectiveness
of vaccines was highly dependent on vaccine characteristics
such as efﬁcacy (with lower efﬁcacy linked to higher
costs),7,15,22,24,30 setting-speciﬁc burden of disease,30 and eco-
nomic considerations such as discount rate,22,30,31 and time
horizon.31
It is important to know the minimum acceptable vaccine
efﬁcacy for designing clinical trials and when making imple-
mentation decisions. Two South African Markov model thresh-
old analyses of new vaccine boosters demonstrated that the
booster strategy would be more effective, and either cost neutral
or more expensive if the booster vaccine demonstrated a vac-
cine efﬁcacy of approximately 40% or above.15,22 The Knight
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et al. study provided contour plots demonstrating the vaccine
efﬁcacies and durations of protection for which the vaccines
would have an above-zero price at which the vaccine would be
cost effective.27 All vaccines in the ranges vaccine efﬁcacy 20-
100% and duration of 5 years to lifelong were cost effective,
and even cost saving above 20% vaccine efﬁcacy and 10 years
duration, when delivered to adolescents and adults.27 However,
the neonatal vaccination program was only cost effective at
higher values of these vaccine characteristics, with no cost effec-
tive vaccine price for a region of the plane where vaccine efﬁ-
cacy and/or duration were relatively low.
Studies identiﬁed post-hoc (n D 2)
For completeness, one unpublished study and one study pub-
lished after the review search date were identiﬁed. The study
published in March 2016 explores the impact of spatial ‘hot-
spot’ targeting compared to random allocation of an adult
POD vaccine in Gujarat, India.33 This model did not compare
vaccine effect types or host infection status or age targeting, but
is the ﬁrst to explore spatial targeting of vaccines, and suggests
spatial targeting could increase impact by 17% in the base case
scenario in this setting.33
The unpublished study is an exploration of the epidemiolog-
ical impact of different future TB vaccine proﬁles when targeted
to adolescents (15 year olds) compared to older adults (60 year
olds) in China.34 This model is a dynamic transmission model
incorporating heterogeneous social mixing patterns by age,
age-speciﬁc natural history parameters, and ﬁtted to age-strati-
ﬁed epidemiological data, and will contribute to the literature
on vaccine age targeting and impact of pre- versus post-infec-
tion vaccines.
Quality assessment (n D 23)
Using the adapted quality assessment tool, scores ranged from
11 to 25 out of 28 (Table 4). Two were considered low qual-
ity,19,23 eight of medium quality,4,13,17,18,25,26,28,29 six high qual-
ity,10,11,14,16,20,30 and seven of very high quality.4,12,15,21,22,27,31
The median score was 20/28, equivalent to high quality. As the
tool was not perfectly suited to analytical papers, the sensitivity
of the median score was assessed by excluding analytical
papers, and the overall score did not change. The major gaps
observed were deﬁnitions of the population and intervention,
ﬁtting methodology, uncertainty and sensitivity analyses, data
sources, and conﬂicts of interest and funding. Comprehensive
uncertainty and sensitivity analyses were lacking in many
studies. Further discussion is included in the supplementary
appendix B.
Discussion
Modeling the epidemiological impact of future TB vaccines is a
relatively young but growing ﬁeld, used to inform rational deci-
sion making in portfolio strategy, prioritization of resources,
and global target setting. To date, the literature remains divided
as to whether vaccines effective pre-infection or post-infection
would provide the greatest epidemiological impact. However,
all-age or adolescent/adult targeted prevention of disease
vaccines achieve greater and more rapid epidemiological
impact than neonatal vaccines. Mass campaigns or boosters
added to routine neonatal vaccination can have profound addi-
tional epidemiological impact. With the exception of one very
low efﬁcacy vaccine and one low burden setting, economic eval-
uations found new TB vaccines to be overwhelmingly cost
effective, particularly when targeted to adolescent/adult age
groups. The variability of impact by setting, age group vacci-
nated, vaccine characteristics and time frame, must be taken
into account in the development and delivery of future
vaccines.
Given the importance of indirect effects in this research
question, the majority of the 23 included studies captured
transmission through development of dynamic models.
Some potential geographical bias was observed, as several
either excluded sub-Saharan Africa or were based upon an
Asia-like epidemic. Although the avoidable burden of dis-
ease may be higher in Asia, the high disease rates and
slower progress toward global targets in the African region
may mean that this region would be in greatest need of
new interventions such as vaccines to meet the WHO 2035
and 2050 targets.3 Epidemiological outcomes were indicative
of considerable heterogeneity by setting, highlighting the
importance of setting-speciﬁc modeling for decision making.
Only four of the models incorporated HIV strata,12,15,27,31
yet globally 12% of all TB cases are HIV co-infected, of
which three-quarters are found in the African Region.3 It is
currently unknown what effect HIV-infection may have on
vaccine efﬁcacy, but it is generally thought that it may be
lower in this population. Therefore, models without HIV
structure may overestimate vaccine impact, and models
including this structure are a useful tool to conduct sensi-
tivity analyses around HIV-related assumptions.
Historically, novel TB vaccine development has focused pri-
marily on vaccination in infancy. However, more recently a
shift in thinking has led to the prioritization of older age groups
in clinical trials and development plans. For prevention of dis-
ease vaccines, this is supported by the modeling literature,
which demonstrates that all-age or adolescent/adult targeted
POD vaccines achieve greater and more rapid epidemiological
impact than neonatal vaccines. This is epidemiologically con-
sistent given that in many settings adults comprise the majority
of the disease burden and their primarily pulmonary disease is
a greater source of M.tb transmission than the extra-pulmonary
disease prevalent in children,3 therefore delivery of POD vac-
cines directly to the adult population provides relatively imme-
diate impact, whereas there is usually a lag of 10-20 years
before any impact of long (>10 years) duration of protection
neonatal vaccination can be seen.
From an implementation perspective, neonatal and adoles-
cent vaccines could potentially be incorporated into existing
delivery platforms, but developing a platform for delivery of
adult vaccination could have serious resource implications.
Although this is an important consideration, one model has
demonstrated that adolescent/adult vaccine targeting would be
more cost effective than neonatal vaccination with a POD vac-
cine.27 Alternatively, several models suggest that addition of
one-off mass campaigns for all ages at initiation of routine neo-
natal vaccination could have a profound effect on the
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population-level impact.19,23,28 No models were identiﬁed com-
paring age targeted POI vaccines or combining age targeting
with targeting to post-infection populations. It was also noticed
by the authors that none of the models explored targeted vacci-
nation of older adults or the elderly, which is surprising given
that several high burden countries are undergoing population
aging (e.g., China, Indonesia) and the higher risk of developing
active disease in this age group.
Our ﬁnding that the modeling literature was equivocal as
to whether post-infection4,20,28 or pre-infection19,35 vaccines
would have greatest epidemiological impact is interesting and
may have important implications. Given the complexity of the
studies, it is not possible to conﬁdently identify the study differ-
ences that explain these diverse ﬁndings. However, there are 2
factors that we believe are likely to be most important. Firstly,
the underlying epidemiology of the population and, in particu-
lar, factors affecting the proportion of disease due to primary
disease and rapid progression versus reactivation or relapse, are
likely to be inﬂuential. This was best illustrated in Dye and Wil-
liams,16 in this study the authors increased rates of treatment of
active disease, which resulted in a switch from greater impact
from a pre-infection vaccine to greater impact from a post-
infection vaccine (Dye and Williams, ﬁgure 6 panels a and b –
by comparing new TB cases per million in 2050 in panel a ver-
sus b at increasing treatment rates per TB case). Increasing the
treatment of active disease reduced transmission and the pro-
portion of disease arising from primary infection (versus reacti-
vation). We recreated this by coding up this model (not shown)
showing that, for the same overall disease burden, when a
greater proportion of disease was due to reactivation the post-
infection vaccines were predicted to have the greater impact
across the full range of rates of treatment of active disease
explored. Secondly, the proportion of the population latently
infected will co-determine the number of people that would
beneﬁt from either a pre- or post-infection vaccine. However,
only two of these six models report the infection preva-
lence.16,20 Another factor that could help explain this difference
is that most of the six models compared assume no relapse
from the recovered class, but in the two models assuming
relapse,4,19 it is possible that relapse rates and assumptions as
to whether this group is protected by post-infection vaccina-
tion, could affect the relative impact of pre- versus post-infec-
tion vaccines. Further, although no major differences were
identiﬁed here, time horizon, vaccine efﬁcacy, and duration of
protection assumptions could also potentially inﬂuence pre- vs.
post-infection outcomes. Given the difﬁculties we have had in
identifying the reasons why these models are making conﬂict-
ing predictions, there is a clear need that these assumptions are
reported carefully in future vaccine modeling studies, and if
this question is important for vaccine development planning,
there may be a need for a controlled modeling study focusing
on this question.
From the vaccine development perspective, although a vac-
cine effective both pre- and post-infection would be the ideal
scenario, pipeline candidates with either pre- or post-infection
efﬁcacy could have value, and modeling could be used to assess
their relative value in different settings. Further, if a candidate
could potentially exhibit different efﬁcacy in infected versus
uninfected populations, efﬁcacy estimates from trials could be
confounded by the balance between primary and reactivation
disease in the trial setting. Or worse, if the recruited population
is limited to either infected or uninfected individuals it is con-
ceivable that a candidate’s development could be discontinued
due to poor efﬁcacy in one population without knowing
whether the candidate would have shown better efﬁcacy in the
other group. Therefore, if proven safe and immunogenic in
both infected and uninfected populations, ideally both should
be recruited into clinical trials and the study powered to esti-
mate vaccine efﬁcacy separately for those IGRA or TST positive
versus negative at recruitment to improve generalizability to
other settings. However, this could make trials infeasibly large,
in which case enrolling both uninfected and infected popula-
tions, but powering the trial on the primary endpoint in one
population, and looking for trend, safety and immunogenicity
in the other population as secondary endpoints may be prefera-
ble to using a combined endpoint.
Upon implementation, sustained campaigns speciﬁcally tar-
geting either uninfected (with a pre-infection vaccine) or
latently infected populations (with a post-infection vaccine)
may not be feasible. To identify such populations, TST or
IGRA testing would be required. Such tests come with cost and
organizational implications, and neither are perfect tests for
latency or the absence of infection.36 Blanket vaccination to
ensure the target population is captured would be an alterna-
tive, but empirical data and modeling would be needed to assess
the costs of vaccine wastage, and consideration given to the
ethics of vaccinating individuals unable to derive direct beneﬁt
from vaccination.
Regarding prevention of disease versus prevention of
infection vaccines, although several studies include vaccines
with these different effect types, there tend to be other
simultaneous changes in the vaccine proﬁles or targeting,
such as age or infection status targeting, which confound
the comparison of the impact of these two vaccine types.
However, overall the studies suggest that prevention of dis-
ease vaccines tend to have a quicker and greater epidemio-
logical impact than prevention of infection vaccines over
the time horizons explored.
Theoretically, it is possible that there could be a genetic pre-
disposition responsible for both ability to control M.tb latent
infection and to respond to a vaccine. For a POD vaccine, this
would become apparent in efﬁcacy trials, as there would be no
impact of such a vaccine on the disease endpoint. However, for
POI vaccine studies with an infection endpoint, such a scenario
could reduce infection rates, but have little impact on popula-
tion level burden of disease as the vaccine may not be effective
in those individuals most likely to progress to disease if
infected. None of the POI vaccine models explored the poten-
tial scenario where vaccine efﬁcacy is linked to likelihood to
progress to disease, but this could be an interesting avenue for
future research.
Although the relative impact of vaccine proﬁles to one
another is informative for rational development of portfolio
strategy, the absolute impact of such programs is important for
understanding the potential role of such new technologies in
achieving global targets and for advocacy for investment. Novel
TB vaccines have the potential to provide an important contri-
bution toward achieving the WHO 2035 and 2050 goals. Yet
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given the ambitious nature of the 2050 targets, even novel vac-
cines may require synergistic pairing with other interventions
to achieve elimination in most modeled scenarios. Due to the
sizeable global pool of latent infection, even a complete trans-
mission block may not achieve elimination because of the con-
tinued burden from reactivation disease. Therefore, prevention
of reactivation disease through vaccination or preventative
treatment of latently infected individuals will be essential to
elimination strategy.
Cost must also be considered when planning implementa-
tion of new TB vaccines, therefore health economic models will
be essential. With the exception of one low-efﬁcacy vaccine
study and one low burden setting,22,30 the studies identiﬁed
found new TB vaccines to be an overwhelmingly cost effective
intervention. The results of threshold analyses are highly con-
text dependent. However, in one analysis of low and middle
income settings, vaccines targeted to adolescents and adults
were shown to be cost effective as low as 20% vaccine efﬁcacy
and ﬁve years duration of protection, whereas infant vaccines
required higher efﬁcacies and longer durations to cross this
threshold over the time horizons considered.27
An adapted tool was developed to assess quality and risk of
bias of included studies for the purposes of this review to sys-
tematically assess reporting, methodological and risk of bias
factors. The majority of included papers were scored as
medium or high quality. The major gaps observed highlight for
future studies the importance of thorough reporting and the
conduct of comprehensive uncertainty and sensitivity analyses.
It is hoped that this quality assessment tool will be of broad use
in future systematic reviews assessing epidemiological models
of other interventions and diseases.
The main limitation of this review was the conduct of inde-
pendent sifting and data extraction by a single reviewer. The
authors recognize that sifting by two independent reviewers
remains the gold standard for systematic reviews.6 However,
due to resource constraints this was not possible, but a very low
threshold was applied for directing sifting queries to a second
reviewer. In addition, the review was ﬁrst conducted in 2014 and
then repeated in 2016, therefore duplication of sifting by the
same primary reviewer was expected to reduce the likelihood of
missing relevant literature. It was found that the study quality
assessment tool developed was not as well suited to assessment
of analytical models as several domains were not applicable,
leading to a higher likelihood of scoring ‘medium’ quality.
Several research gaps were identiﬁed in this analysis of the
available literature. The lack of a clear explanation for the polari-
zation of outcomes for pre-infection and post-infection vaccines
is troubling, therefore a model to explore which key determi-
nants within the model impact these outcomes would be an
important addition to the literature. None of the models pre-
sented explicitly explored the potential impact of targeting vac-
cines to older adult or elderly populations. Such a model would
be pertinent for a country such as China, which has high disease
burden, an aging population, and has only been brieﬂy explored
in one sub-model in the literature. Future vaccines could be
important in tackling multi-drug resistance disease through pre-
vention of transmission or disease, yet drug resistance was not
explored in any of the models identiﬁed. Few of the models
included non-random social mixing patterns, and none
considered the potential impact of evolving mixing patterns on
the impact of vaccines. Some studies have explored the epidemi-
ological impact of vaccine age targeting in sub-Saharan Africa;
however, these models were either missing HIV structure, did
not explore reduction of vaccine efﬁcacy in HIV-infected indi-
viduals, only considered vaccination of uninfected populations,
or were static models. Given HIV co-infection and high forces of
M.tb infection are fundamental to the epidemic in many sub-
Saharan African countries, there is a need for a comprehensive
model incorporating these important elements.
Conclusion
Mathematical modeling has been used to understand how the
epidemiological impact of future vaccines could be altered by
vaccine characteristics, vaccine age targeting, and epidemiologi-
cal setting. It has also proved important for exploring the
potential role of new vaccines for achieving the WHO 2050
goal of tuberculosis elimination. Such modeling should be inte-
gral to the development of future TB vaccines, informing ratio-
nal decision making by cross-product bodies, academia,
industry and policy makers for the development, investment
and implementation of pipeline vaccines.
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